Trial Profile
An observational study to assess the incidence, treatment and evolution of immune-related adverse events due to Immune checkpoint blockade therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Sep 2020
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Lung cancer; Malignant melanoma; Renal cancer; Solid tumours
- Focus Adverse reactions
- 03 Sep 2020 Results published in the Clinical and Experimental Rheumatology
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
- 26 Nov 2018 New trial record